MARKET

ABBV

ABBV

Abbvie Inc
NYSE
178.99
+0.18
+0.10%
Pre Market: 179.19 +0.2 +0.11% 04:07 02/28 EST
OPEN
178.77
PREV CLOSE
178.81
HIGH
179.53
LOW
176.98
VOLUME
4
TURNOVER
0
52 WEEK HIGH
179.79
52 WEEK LOW
127.03
MARKET CAP
316.18B
P/E (TTM)
65.84
1D
5D
1M
3M
1Y
5Y
AbbVie And OSE Immunotherapeutics Enter Strategic Partnership To Develop A Novel Monoclonal Antibody For The Treatment Of Chronic Inflammation
Benzinga · 1h ago
AbbVie partners with OSE Immunotherapeutics to develop novel nonoclonal antibody
Healthcare AbbVie partners with OSE Immunotherapeutics to develop novel nonoclonal antibody. OSE-230 is a monoclonals antibody designed to resolve chronic and severe inflammation. Abbvie will receive an exclusive global license to develop, manufacture and commercialize the antibody.
Seeking Alpha · 2h ago
AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics
NASDAQ · 3h ago
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation. OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments. AbbVie will receive an exclusive global license to develop and commercialize OSE.
PR Newswire · 4h ago
Top 25 Stocks in the S&P 500 By Index Weight for March 2024
The top 25 stocks in the S&P 500 by weight represent the largest, most influential companies in the index. February saw continued gains in the tech giants like Microsoft, Apple, Nvidia, and Amazon. The information technology, financials, healthcare, and consumer discretionary sectors carry a combined weight of 66%. The top seven tech companies make up 62% of the top 25 by weight.
Investopedia · 15h ago
First Week of January 2026 Options Trading For AbbVie (ABBV)
NASDAQ · 17h ago
Genmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDA
NASDAQ · 19h ago
ABBV Crosses Above Average Analyst Target
NASDAQ · 21h ago
More
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, ELAHERE, IMGN-151, Pivekimab Sunirine and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities and more. The Company offers a PINK1 activator which is designed to address mitochondrial dysfunction.

Webull offers AbbVie Inc stock information, including NYSE: ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.